11/10/2026 updated

CH
100 % available

CMO/SVP Clinical Development & Regulatory Affairs | Entrepreneurial C-Level Executive | M.D.

Menlo Park, USA
Worldwide
M.B., B.S. - Middlesex Hospital Medical School, University of London
Menlo Park, USA
Worldwide
M.B., B.S. - Middlesex Hospital Medical School, University of London

Profile attachments

CV Colin Hislop_ Abbreviated Nov 2026.pdf

About me

Entrepreneurial C-level executive. Over 38 years pharma experience: pre-IND to Phase IV across a broad range of therapeutic areas. Secured over $450MM in financing including IPO. In- and out-license diligence. Filed and prosecuted multiple NDAs/MAAs. Prix Galien nominee 2022 Zokinvy®

Clinical Development Strategy
Expertise spanning all phases of drug development from pre-IND to Phase IV post-marketing support, including design and implementation of clinical development programs across a broad range of therapeutic areas such as rare diseases, cardiovascular, infectious diseases, and autoimmune conditions.

Regulatory Affairs & NDA/MAA Submissions
Extensive track record in filing and prosecuting multiple NDAs for NCEs, including the successful NDA and MAA approval of lonafarnib (Zokinvy) for Hutchinson-Gilford Progeria Syndrome. Leadership of global regulatory interactions with FDA, EMA, PMDA, and other agencies.

Venture Capital Fundraising & Investor Relations
Proven ability to secure significant financing in start-up and growth-stage pharmaceutical environments, having raised over $450 million in venture capital, private and public financing including IPO participation and follow-on offerings.

CRO Management & Outsourcing
Extensive experience in CRO selection, contract negotiation, scope definition, and management of clinical development plans through CRO partnerships, including budget, manpower, and timeline oversight.

Portfolio & Program Management
Portfolio management for NCE development including departmental budget management, manpower planning, and oversight of multi-function matrix project teams across large-scale international programs.

In-License & Out-License Diligence
Hands-on experience in in-license and out-license diligence activities, including negotiation of out-license partnerships and business development evaluation of M&A, licensing, and partnership opportunities.

Medical & Scientific Leadership
Clinical and scientific leadership of pharmaceutical organizations, including line management of MDs, supervisory responsibilities for Clinical Development organizations, and establishment of scientific and clinical advisory boards.

Integrated Non-Clinical/Clinical Strategy
Definition of integrated non-clinical and clinical strategies for drug development programs, covering development of both small and large molecules from pre-IND through to marketing approval.

Therapeutic Area Expertise
Broad therapeutic area experience including ultra-rare genetic pediatric disease, cardiovascular disease, infectious diseases, autoimmune disease, endocrine diseases, renal disease, CNS disease, cystic fibrosis, and growth hormone deficiency.

Experience

Professional experience10+ years
Freelancer since2018

Languages

EnglishNative speaker

Project history

Senior Vice President, Clinical & Development Operations

Juvena Therapeutics
Development strategy, design and implementation of clinical development programs, regulatory strategy, and member of Management Team. Working with a fusion protein in the field of muscle regeneration, advancing from pre-IND/IND to Phase 1 FIH studies and onto a Phase 1/2a mechanistic PoC study.

Founder

Colin Hislop Pharma Consulting LLC
Operational and strategic drug development consulting services to the pharmaceutical industry. Clients include EIT Pharma (2024-present), Trellis Biosciences (2018-present), and Sentynl Therapeutics (2024-present).

President & CEO

Ridgeway Therapeutics
Founder of an immuno-oncology biotech start-up company, now dormant.

Senior Vice President, Clinical & Development Operations

Eiger Biopharmaceuticals
Led clinical development programs for treatments of chronic hepatitis D infection. Prosecuted Zokinvy NDA and MAA. Member of Management Team. Eiger filed for bankruptcy in April 2024 due to inability to close a financing.

Senior Medical Advisor

Eiger Biopharmaceuticals
Medical monitoring of HDV programs and assessment of new potential development opportunities.

Chief Medical Officer

Versartis Inc.
Clinical and scientific leadership of the company, KOL development, and investor interface, financing, and presentations.

Chief Medical Officer and Senior Vice President Clinical Development

Anthera Pharmaceuticals
Clinical and scientific leadership of the company, investor interface, presentation updates and financing, including the March 2010 $70 million IPO and several follow-on financings.

Senior Vice President Clinical Development

Anthera Pharmaceuticals
Member of the founding senior management team. Strategy and execution for the company's lead program in cardiovascular disease. Private and public equity financing over $350 million. Business development evaluation of new M&A, licensing and partnership opportunities. Establishment of scientific and clinical advisory boards. IND preparation, FDA and EMEA meetings. Protocol development, CRO selection, study execution, and staff recruitment.

Vice President & Head of Clinical Development

Peninsula Pharmaceuticals
Developed and implemented the strategic vision for the clinical development organization. Provided strategic and operational direction for development, execution, monitoring and interpretation of clinical studies. Implemented clinical development infrastructure. Led an organization of over 25 employees and contractors. Peninsula was acquired by Johnson & Johnson in June 2005.

Vice President, Clinical Research

CV Therapeutics
Vice President of clinical research for the company's flagship product Ranolazine. Managed and mentored a small group of physicians, managed and oversaw ongoing and new clinical studies, attended pre-NDA meetings with FDA, led the writing, preparation and submission of the Ranolazine NDA, and managed the response to clinical questions during the prosecution of the NDA.

Medical Director, Cardiovascular & Internal Medicine, New Drug Development

Procter & Gamble Pharmaceuticals
Led the preparation of an NDA (Cardio-Renal division FDA). Portfolio management of cardiovascular and internal medicine products. Execution of early Phase II/Proof-of-Concept studies. Pre-IND meetings and IND preparation. Developmental management responsibilities for a class III anti-arrhythmic agent. Line management and supervisory responsibilities.

Worldwide Clinical Development Manager, Risedronate

Procter & Gamble Pharmaceuticals
Successful filing and prosecution of global regulatory applications for a bisphosphonate (Actonel) with indications in Paget's disease and Osteoporosis. Preparation of a comprehensive international clinical development plan. Selection of CROs, scope definition and contract negotiation. Management of budget, manpower and timelines. Strategic planning, implementation and prosecution of regulatory filings.

Medical Director, P&GP UK

Procter & Gamble Pharmaceuticals
Recruited to build de novo a medical department capable of supporting the UK business needs and executing Phase III, IIIB and IV studies. Assumed responsibility for approval of advertising copy and interacted with the UK regulatory agency (MCA). Two PLAs were successfully prosecuted.

Medical Advisor, Endocrinology

Eli Lilly & Company
Support of the UK business through Phase IIIB and IV studies. Responsibility for a mixed portfolio of compounds ranging from human insulin and growth hormone to pulmonary and CNS drugs. Wrote protocols for and oversaw the execution of numerous UK and European Phase IIB, III and IV studies. Wrote the clinical expert report for a PLA in the CNS area.

Contact form

Log in to get in touch

You need to be logged in to use the contact form.

Sign upLog in